Trusting Your Gut: *Optimizing Treatment for Rett: Part of the Project Horizon Initiative*

Resource	Address
A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome. ClinicalTrials.gov identifier: NCT05898620. Last Update: June 10, 2026.	https://clinicaltrials.gov/study/NCT05898620
A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study). ClinicalTrials.gov identifier: NCT05606614. Last Update: July 7, 2026.	https://clinicaltrials.gov/study/NCT05606614
Aishwarya R, Abdullah CS, Morshed M, Remex NS, Bhuiyan MS. Sigmar1's molecular, cellular, and biological functions in regulating cellular pathophysiology. *Front Physiol*. 2021;12:705575.	https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2021.705575/full
Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet*. 1999;23:185-188.	https://www.nature.com/articles/ng1099_185
An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome (DAFFODIL™). ClinicalTrials.gov identifier: NCT04988867. Last Update: September 24, 2024.	https://clinicaltrials.gov/study/NCT04988867
ANAVEX2-73 Study in Patients With Rett Syndrome (AVATAR). ClinicalTrials.gov identifier: NCT03941444. Last Update Posted: January 27, 2022.	https://clinicaltrials.gov/study/NCT03941444
Anderson A, Wong K, Jacoby P, Downs J, Leonard H. Twenty years of surveillance in Rett syndrome: What does this tell us? *Orphanet J Rare Dis*. 2014;9:87.	https://link.springer.com/article/10.1186/1750-1172-9-87
Busner J, Targum SD. The clinical global impressions scale: Applying a research tool in clinical practice. *Psychiatry (Edgmont)*. 2007;4:28-37.	https://pmc.ncbi.nlm.nih.gov/articles/PMC2880930/
Cobb S, Ross P, Hector RD, et al. 824. A self-regulating gene therapy for rett syndrome. *Mol Ther*. 2022;30(4_suppl 1):393.	https://www.sciencedirect.com/science/article/pii/S1525001622002465
Cosand L, Mayman H, Downs J, Abler V. Real-world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study. *Dev Med Child Neurol*. 2026;68:407-417.	https://onlinelibrary.wiley.com/doi/10.1111/dmcn.16482
Fang Y, Luo Y, Yu J, Chen J. A case of severe malnutrition infant with neonatal onset intractable diarrhea. *BMC Pediatr*. 2020;20:133.	https://link.springer.com/article/10.1186/s12887-020-1999-0
Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. *BMJ Paediatr Open*. 2020;4:e000717.	https://bmjpaedsopen.bmj.com/content/4/1/e000717
Gold WA, Percy AK, Neul JL, et al. Rett syndrome. *Nat Rev Dis Primers*. 2024;10:84.	https://www.nature.com/articles/s41572-024-00568-0
Hagberg B, Witt-Engerström I, Opitz JM, Reynolds JF. Rett syndrome: A suggested staging system for describing impairment profile with increasing age	https://onlinelibrary.wiley.com/doi/10.1002/ajmg.1320250506

towards adolescence. *Am J Med Genet*. 1986;1:47-59.	
Hudu SA, Elmigdadi F, Qtaitat AA, et a. Trofinetide for Rett syndrome: Highlights on the development and related inventions of the first USFDA-approved treatment for rare pediatric unmet medical need. *J Clin Med*. 2023;12:5114.	https://www.mdpi.com/2077-0383/12/15/5114
Ihekweazu FD, Motil KJ. Gastrointestinal manifestations of Rett syndrome: An updated analysis using the Gastrointestinal Health Questionnaire. *J Pediatr Gastroenterol Nutr*. 2025;80:46-56.	https://onlinelibrary.wiley.com/doi/10.1002/jpn3.12394
Kaufmann WE, Sprouse J, Rebowe N, Hanania T, Klamer D, Missling CU. ANAVEX® 2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome. *Pharmacol Biochem Behav*. 2019;187:172796.	https://www.sciencedirect.com/science/article/abs/pii/S0091305719302515
Keam SJ. Trofinetide: First approval. *Drugs*. 2023;83:819-824.	https://link.springer.com/article/10.1007/s40265-023-01883-8
Kyle SM, Vashi N, Justice MJ. Rett syndrome: A neurological disorder with metabolic components. *Open Biol*. 2018;8:170216.	https://royalsocietypublishing.org/rsob/article/8/2/170216/91629/Rett-syndrome-a-neurological-disorder-with
Macfarlane S, Grimmer T, Teo K, et al. Blarcamesine for the treatment of Early Alzheimer's disease: Results from the ANAVEX2-73-AD-004 phase IIB/III trial. *J Prev Alzheimers Dis*. 2025;12:100016.	https://www.sciencedirect.com/science/article/pii/S2274580724006083
Master of Pediatrics. Current Treatments & Emerging Treatments for Rett Syndrome. January 16, 2023.	https://mastersofpediatrics.com/articles/current-treatments-emerging-treatments-for-rett-syndrome/
May D, Kponee-Shovein K, Mahendran M, et al. Epidemiology and patient journey of Rett syndrome in the United States: A real-world evidence study. *BMC Neurol*. 2023;23:141.	https://link.springer.com/article/10.1186/s12883-023-03181-y
May D, Kponee-Shovein K, Neul JL, et al. Characterizing the journey of Rett syndrome among females in the United States: A real-world evidence study using the Rett syndrome natural history study database. *J Neurodev Disord*. 2024;16:42.	https://link.springer.com/article/10.1186/s11689-024-09557-6
Merritt JK, Fang X, Caylor RC, Skinner SA, Friez MJ, Percy AK, Neul JL. Normalized clinical severity scores reveal a correlation between X chromosome inactivation and disease severity in Rett syndrome. *Genes (Basel)*. 2024;15:594.	https://www.mdpi.com/2073-4425/15/5/594
Motil KJ, Beisang A, Smith-Hicks C, Lembo A, Standridge SM, Liu E. Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in Rett syndrome. *Expert Rev Gastroenterol Hepatol*. 2024;18:227-237.	https://www.tandfonline.com/doi/full/10.1080/17474124.2024.2368014
Neul JL, Benke TA, Marsh ED, et al. Top caregiver concerns in Rett syndrome and related disorders: data from the US natural history study. *J Neurodev*	https://link.springer.com/article/10.1186/s11689-023-09502-z

***Disord*. 2023;15:33.**	
Neul JL, Fang P, Barrish J, et al. Specific mutations in *methyl-CpG-binding protein 2* confer different severity in Rett syndrome. *Neurology*. 2008;70:1313-1321.	https://www.neurology.org/doi/10.1212/01.wnl.0000291011.54508.aa
Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: Revised diagnostic criteria and nomenclature. *Ann Neurol*. 2010;68:944-950.	https://onlinelibrary.wiley.com/doi/10.1002/ana.22124
Neul JL, Percy AK, Benke TA, et al. Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome. *Contemp Clin Trials*. 2022;114:106704.	https://www.sciencedirect.com/science/article/pii/S1551714422000301
Neul JL, Percy AK, Benke TA, et al. Trofinetide for the treatment of Rett syndrome: A randomized phase 3 study. *Nat Med*. 2023;29:1468-1475.	https://www.nature.com/articles/s41591-023-02398-1
NORD (National Organization For Rare Disorders). Rett Syndrome. Last updated: March 15, 2023.	https://rarediseases.org/rare-diseases/rett-syndrome/
Parent H, Ferranti A, Niswender C. Trofinetide: A pioneering treatment for Rett syndrome. *Trends Pharmacol Sci*. 2023;44:740-741.	https://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147(23)00135-9
Pejhan S, Rastegar M. Role of DNA methyl-CpG-binding protein MeCP2 in Rett syndrome pathobiology and mechanism of disease. *Biomolecules*. 2021;11:75.	https://www.mdpi.com/2218-273X/11/1/75
Percy AK, Ananth A, Neul JL. Rett syndrome: The emerging landscape of treatment strategies. *CNS Drugs*. 2024;38:851-867.	https://link.springer.com/article/10.1007/s40263-024-01106-y
Percy AK, Lane JB, Childers J, et al. Rett syndrome: North American database. *J Child Neurol*. 2007;22:1338-1341.	https://journals.sagepub.com/doi/10.1177/0883073807308715
Percy AK, Neul JL, Benke TA, et al. Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study. *Med*. 2024;5:1275-1281.e2.	https://www.sciencedirect.com/science/article/pii/S2666634024002538
Percy AK, Neul JL, Benke TA, et al. Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study. *Med*. 2024;5:1178-1189.e3.	https://www.sciencedirect.com/science/article/pii/S2666634024002228
Percy AK, Neul JL, Benke TA, Marsh ED, Glaze DG. A review of the Rett Syndrome Behaviour Questionnaire and its utilization in the assessment of symptoms associated with Rett syndrome. *Front Pediatr*. 2023;11:1229553.	https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2023.1229553/full
Percy AK, Ryther R, Marsh ED, et al. Results from the phase 2/3 DAFFODIL study of trofinetide in girls aged 2-4 years with Rett syndrome. *Med*. 2025;6:100608.	https://www.sciencedirect.com/science/article/pii/S2666634025000352
Powers S, Likhite S, Gadalla KK, et al. Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates. *Mol Ther*. 2023;31:2767-2782.	https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(23)00393-3

Rett Dialogue. Understanding Rett syndrome. 2025.	https://rettdialogue.com/aboutrett/
Rossignol E, et al. REVEAL adolescent/adult and pediatric clinical trial update: safety and efficacy data on TSHA-102 AAV9 investigational gene therapy in clinical evaluation for Rett syndrome. Poster presented at: 2025 IRSF Rett Syndrome Scientific Meeting; June 9-11, 2025; Boston, MA.	https://www.rettsyndrome.org/event/2025-irsf-rett-syndrome-scientific-meeting/
Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study). ClinicalTrials.gov identifier: NCT06152237. Last Update: October 15, 2025.	https://clinicaltrials.gov/study/NCT06152237
Singh A, Balasundaram MK, Gupta D. Trofinetide in Rett syndrome: A brief review of safety and efficacy. *Intractable Rare Dis Res.* 2023;12:262-266.	https://www.jstage.jst.go.jp/article/irdr/12/4/12_2023.01060/_article
Sinnett SE, Boyle E, Lyons C, Gray SJ. Engineered microRNA-based regulatory element permits safe high-dose miniMECP2 gene therapy in Rett mice. *Brain*. 2021;144:3005-3019.	https://academic.oup.com/brain/article/144/10/3005/6265600
Study of ANAVEX2-73 in Patients With Rett Syndrome. ClinicalTrials.gov identifier: NCT03758924. Last Update: January 12, 2021.	https://clinicaltrials.gov/study/NCT03758924
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™). ClinicalTrials.gov identifier: NCT04181723. Last Update: April 8, 2024.	https://clinicaltrials.gov/study/NCT04181723
Suter B, Lieberman D, Benke T, et al. NGN-401, a novel regulated gene therapy for Rett syndrome: Preliminary results from the first-in-human study. Poster presented at: British Paediatric Neurology Association (BPNA) Annual Conference; January 8-10, 2025; Oxford, UK.	https://onlinelibrary.wiley.com/doi/10.1111/dmcn.16181
Trappe R, Laccone F, Cobilanschi J, et al. *MECP2* mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. *Am J Hum Genet*. 2001;68:1093-1101.	https://www.cell.com/ajhg/pdf/S0002-9297(07)61218-X.pdf

All URLs Accessed October 13, 2026.